IBA signs contract with Istituto Clinico Humanitas for a Proteus®ONE proton therapy solution in Italy
30 Juin 2022 - 7:00AM
IBA signs contract with Istituto Clinico Humanitas for a
Proteus®ONE proton therapy solution in Italy
Louvain-La-Neuve, Belgium, June 30, 2022
– IBA (Ion Beam Applications S.A., EURONEXT), the world
leader in particle accelerator technology and the world’s leading
provider of proton therapy solutions for the treatment of cancer,
today announces it has signed a contract with Istituto Clinico
Humanitas (Humanitas Research Hospital) for the installation of a
Proteus®ONE1 compact proton therapy solution in Rozzano (Milan),
Italy. IBA will start to recognize the revenue of this contract in
2022.
The proton therapy solution will be installed at
the Humanitas Cancer Center and includes a
Proteus®ONE solution as well as a fully integrated
quality assurance (QA) hardware and software package from IBA
Dosimetry. The contract includes long-term operation and
maintenance services to be provided by IBA. Istituto Clinico
Humanitas expects to start treating patients by 2025.
The typical end-user price for a Proteus®ONE
system with a 10-year maintenance contract ranges between EUR 35-45
million.
Olivier Legrain, Chief Executive Officer
of IBA, commented: “This deal with Humanitas reinforces
our position as a global market leader in proton therapy and
further highlights the increase in activity that we are seeing in
Europe and at the global scale. It is the third Proteus®ONE deal
secured in Italy and the fourth IBA proton therapy system sold in
the country overall. Humanitas is renowned for its innovative
cancer treatments, and we look forward to supporting the center in
our joint mission of providing cancer patients with access to the
most advanced treatment options.”
Luciano Ravera, Chief Executive Officer
of Istituto Clinico Humanitas, added: “We are glad to
partner with IBA to make increasingly advanced treatments available
to our patients. The proton center will further enhance the
services of the Humanitas Cancer Center, and in particular its
radiotherapy team, which already takes care of thousands of
patients from all over Italy and beyond. Proton therapy is an
advanced and innovative form of radiotherapy and nowadays
represents a new treatment choice for many types of cancer.
Research collaborations will also benefit from this new service,
enabling us to contribute to the development of international
studies with the community of other proton therapy users.”
***ENDS***
About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,500 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
About Humanitas
Humanitas is a highly specialised hospital,
research and teaching center, which hosts Humanitas University, an
academic institute dedicated to medical sciences. Built around
centers for the prevention and treatment of cancer, cardiovascular,
neurological, autoimmune, inflammatory, and orthopedic diseases,
Istituto Clinico Humanitas also operates a highly specialised
Emergency Department and the Emergency Hospital 19, dedicated to
the treatment of infectious diseases. Humanitas is the first
Italian hospital quality-certified by Joint Commission
International since 2018 as Academic Hospital, and it is accredited
by Italy’s National Health Service. Appointed as an IRCCS by the
Ministry of Health (an accreditation in the Italian system that
acknowledges institutions focused on excellence in clinical care
and research), Humanitas is an internationally well-known research
center with focus on immune system-related diseases. Istituto
Clinico Humanitas is the flagship of a hospital group also present
in Milan, Bergamo, Turin, Catania and Castellanza (Varese).
More information can be found at :
https://www.humanitas.it/
CONTACTS
Soumya ChandramouliChief
Financial Officer+32 10 475 890Investorrelations@iba-group.com
Olivier LechienCorporate
Communication Director+32 10 475 890communication@iba-group.com
Consilium Strategic
CommunicationsAmber Fennell, Angela Gray, Lucy
Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com
1 Proteus®ONE is the brand name of Proteus®235
- 220630_Humanitas_Contract-P1-Rozzano-EN-2
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024